Christine Bunt is the CEO of Verseau Therapeutics. She is a serial entrepreneur, investor, founder, and CEO of life sciences companies. She is a partner with 20/20 HealthCare Partners, a private global investment group, managing clients in the biotechnology sector. Prior to joining Verseau, Christine was the CEO and Founder of INTICA Biomedical and of TARIS Biomedical, a Deshpande spinout that she cofounded.

Christine’s prior roles include leadership positions in inflammation, neuroscience, and cardiovascular products at Merck & Co., as well as R&D, business management, and commercialization functions at Hoffmann-La Roche. She holds degrees in medical technology and immunochemistry from the Institute for Hygiene and Infectious Diseases/Medical School of the University of Saarbrücken in Germany.

Christine serves on boards at Beth Israel Deaconess Medical Center and the Harvard Medical School Initiative for RNA Medicine.